Cluster of Excellence –
University of Freiburg

Prof. Dr. Silke Lassmann

Prof. Dr. Silke Lassmann

Institute of Surgical Pathology, Department of Pathology,
University Medical Center Freiburg

+49 761 270 80620

 

Our research group is interested in “molecular tumorpathology”, focussing on the biology of solid tumours by translational approaches. Our aim is to decipher basic molecular mechanisms of tumour development and progression, in particular with respect to (epi-)genetic instability and signalling pathways. We envisage using this basic molecular knowledge to evaluate novel applications of molecular pathology in a clinically-relevant setting, specifically addressing the issue of therapy prediction. In this context, we continuously work on new development or the “fine-tuning” of “state of the art” techniques for application to human tissue specimens. Close collaboration with other pathology- and clinic-based research groups as well as with researcher groups in the field of material and natural sciences and biostatistics greatly support our research goals.

 

 

10 selected publications

  • Fibroblast activation protein-α, a stromal cell surface protease, shapes key features of cancer associated fibroblasts through proteome and degradome alterations.
    Koczorowska MM, Tholen S, Bucher F, Lutz L, Kizhakkedathu JN, De Wever O, Wellner UF, Biniossek ML, Stahl A, Lassmann S, Schilling O (2016).
    Mol Oncol. 10(1):40-58.
  • Response of esophageal cancer cells to epigenetic inhibitors is mediated via altered thioredoxin activity.
    Ahrens TD, Timme S, Ostendorp J, Bogatyreva L, Hoeppner J, Hopt UT, Hauschke D, Werner M, Lassmann S (2016).
    Lab Invest. 96(3):307-16
  • Subcellular localization of EGFR in esophageal carcinoma cell lines.
    Spohn L, Fichter C, Werner M, Lassmann S (2016).
    J Cell Commun Signal. 10(1):41-7.
  • Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD, Timme S, Hoeppner J, Ostendorp J, Hembach S, Follo M, Hopt UT, Werner M, Busch H, Boerries M, Lassmann S (2015).
    Epigenetics 10(5):431-45.
  • B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells.
    Herr R, Köhler M, Andrlova H, Weinberg F, Möller Y, Halbach S, Lutz L, Mastroianni J, Klose M, Bittermann N, Kowar S, Zeiser R, Olayioye MA, Lassmann S, Busch H, Boerries M, Brummer T (2015).
    Cancer Res. 75(1):216-29.
  • Metadherin exon 11 skipping variant enhances metastatic spread of ovarian cancer.
    Haug S, Schnerch D, Halbach S, Mastroianni J, Dumit VI, Follo M, Hasenburg A, Köhler M, Dierbach H, Herzog S, Proske A, Werner M, Dengjel J, Brummer T, Lassmann S, Wäsch R, Zeiser R (2015).
    Int J Cancer. 136(10):2328-40.
  • EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
    Fichter CD, Timme S, Braun JA, Gudernatsch V, Schöpflin A, Bogatyreva L, Geddert H, Faller G, Klimstra D, Tang L, Hauschke D, Werner M, Lassmann S (2014).
    Int J Cancer. 135(7):1517-30.
  • ErbB targeting inhibitors repress cell migration of esophageal squamous cell carcinoma and adenocarcinoma cells by distinct signaling pathways.
    Fichter CD, Gudernatsch V, Przypadlo CM, Follo M, Schmidt G, Werner M, Lassmann S.
    J Mol Med (Berl). 2014 Aug 6. [Epub ahead of print]
  • STAT3 expression, activity and functional consequences of STAT3 inhibition in esophageal squamous cell carcinomas and Barrett's adenocarcinomas.
    Timme S, Ihde S, Fichter CD, Waehle V, Bogatyreva L, Atanasov K, Kohler I, Schöpflin A, Geddert H, Faller G, Klimstra D, Tang L, Reinheckel T, Hauschke D, Busch H, Boerries M, Werner M, Lassmann S (2014).
    Oncogene. 33(25):3256-66.
  • ID2 and ID3 protein expression mirrors granulopoietic maturation and discriminates between acute leukemia subtypes.
    May AM, Frey AV, Bogatyreva L, Benkisser-Petersen M, Hauschke D, Lübbert M, Wäsch R, Werner M, Hasskarl J, Lassmann S (2014).
    Histochem Cell Biol. 141(4):431-40.